Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
As obesity evolves as a global pandemic, the use of drugs to treat it is booming. The latest among these are Glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Along with their use, the incidence of adverse events has become more common. Although severe effects have been mentioned, details and a...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2024-08-01
|
| シリーズ: | Endocrines |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/2673-396X/5/3/23 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|